Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
| ▸ | AKR1A1 | P14550 | 16/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 16/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22380712 | 0.85 | AKR1A1 (0.64) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL25892639 | 0.85 | ITGA4 (0.58) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL21095582 | 0.81 | ITGA4 (0.58) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL21095592 | 0.80 | ITGA4 (0.61) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL21095591 | 0.80 | ITGA4 (0.57) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL25892568 | 0.77 | ITGA4 (0.57) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL20845781 | 0.77 | ITGA4 (0.60) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL25063678 | 0.77 | ITGA4 (0.60) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL31195728 | 0.77 | ITGA4 (1.00) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 | |
| SCHEMBL9810959 | 0.77 | ITGA4 (1.00) | ITGA4AKR1A1AKR1B1CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | ITGA4 4749/4885AKR1A1 3/4885AKR1B1 1/4885 |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | ITGA4 4832/4885AKR1A1 8/4885AKR1B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.